Eli Lilly: Market Overreacted

On January 14th, Eli Lilly (NYSE: LLY ) released updated revenue guidance for Q4 FY24, with a $400 million reduction from the previously issued forecast. The stock dropped over 8% that day, which, I think, was disproportionate to a small 0.6% reduction in revenue projections.We bring a rigorous research-driven approach to uncovering high-conviction stocks with compelling growth potential across dynamic sectors like big tech, semiconductors, AI, and healthcare. Leveraging comprehensive sector insights, We an ...